211At-labeled monoclonal antibody MX35

Subscribe to Selected New Research on 211At-labeled monoclonal antibody MX35

3 relevant articles (2 outcomes, 0 trials/studies) found for this Bio-Agent

Description: a radiopharmaceutical for radioimmunotherapy of ovarian cancer

Also Known As:

211At-MX35

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lindegren, Sture: 2 articles (11/2006 - 11/2006)
2.	Bäck, Tom: 2 articles (11/2006 - 11/2006)
3.	Jensen, Holger: 2 articles (11/2006 - 11/2006)
4.	Hultborn, Ragnar: 2 articles (11/2006 - 11/2006)
5.	Olsson, Marita: 2 articles (11/2006 - 11/2006)
6.	Andersson, Håkan: 2 articles (11/2006 - 11/2006)
7.	Claesson, Ingela: 2 articles (11/2006 - 11/2006)
8.	Jacobsson, Lars: 2 articles (11/2006 - 11/2006)
9.	Elgqvist, Jörgen: 2 articles (11/2006 - 11/2006)
10.	Palm, Stig: 2 articles (11/2006 - 11/2006)

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 11/01/2006 - "Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity." 11/15/2006 - "Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2." 08/01/2006 - "The purpose of this work was to (a) investigate the efficacy of radioimmunotherapy using 211At-MX35 F(ab')2 or 211At-Rituximab F(ab')2 (nonspecific antibody) against differently advanced ovarian cancer in mice; (b) image the tumor growth on the peritoneum; and (c) calculate the specific energy and mean absorbed dose to tumors and critical organs" Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 08/01/2006 - "CONCLUSION: Treatment with 211At-MX35 F(ab')2 or 211At-Rituximab F(ab')2 resulted in a TFF of 95%-100% when the tumor radius was < or =30 microm" 08/01/2006 - "RESULTS: When given treatment 1, 3, 4, 5, or 7 wk after cell inoculation the tumor-free fraction (TFF) was 95%, 68%, 58%, 47%, 26%, and 100%, 80%, 20%, 20%, and 0% when treated with 211At-MX35 F(ab')2 or 211At-Rituximab F(ab')2, respectively" 08/01/2006 - "The purpose of this work was to (a) investigate the efficacy of radioimmunotherapy using 211At-MX35 F(ab')2 or 211At-Rituximab F(ab')2 (nonspecific antibody) against differently advanced ovarian cancer in mice; (b) image the tumor growth on the peritoneum; and (c) calculate the specific energy and mean absorbed dose to tumors and critical organs" Get all the results and reference details, order at left...
2 Diseases and 3 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	AB 2
1 Drugs and Important Bio-Agents and 3 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Radioimmunotherapy
1 Therapies and Procedures and 3 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>